<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302807</url>
  </required_header>
  <id_info>
    <org_study_id>GO29294</org_study_id>
    <secondary_id>2014-003231-19</secondary_id>
    <nct_id>NCT02302807</nct_id>
  </id_info>
  <brief_title>A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]</brief_title>
  <official_title>A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study
      designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in
      participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have
      progressed during or following a platinum-containing regimen. The anticipated time on study
      treatment is based on continued clinical benefit, i.e., until disease progression or
      unacceptable toxicity. The target sample size is 931 participants.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 13, 2015</start_date>
  <completion_date type="Anticipated">May 29, 2018</completion_date>
  <primary_completion_date type="Actual">March 13, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Between randomization and death due to any cause, up to approximately 25 months after first participant enrolled</time_frame>
    <description>OS was defined as time from randomization to death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) as Determined by the Investigator With Use of RECIST v1.1</measure>
    <time_frame>Up to approximately 25 months after first participant enrolled</time_frame>
    <description>PFS was defined as the time between the date of randomization and the date of first documented progression of disease (PD) or death, whichever occurred first. PD was determined on the basis of investigator assessment with use of RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters had to demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) as Determined by the Investigator With Use of RECIST v1.1</measure>
    <time_frame>Up to approximately 25 months after first participant enrolled</time_frame>
    <description>DOR was defined as the time from first occurrence of a CR or PR, whichever came first, to first documented PD or death, whichever occurred first. Disease progression was determined on the basis of investigator assessment with use of RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 25 months after first participant enrolled</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-therapeutic Antibodies (ATA) to Atezolizumab</measure>
    <time_frame>Predose (0 hours) on Day 1 of Cycles 1, 2, 3, 4 and every 8 cycles thereafter; at treatment discontinuation (up to 25 months); at 120 days after last dose of atezolizumab (up to 25 months; each cycle is 21 days)</time_frame>
    <description>Participants were considered post-baseline ATA positive if they had post-baseline ATAs to Atezolizumab that were treatment-induced or treatment-enhanced. Participants had treatment-induced ATAs if they had a baseline-negative ATA result and developed ATAs at any time after initial drug administration. Participants had treatment-enhanced ATAs if they had a baseline-positive ATA result that showed an enhanced signal that was &gt;/= 0.60 titer units at any time after initial drug initiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Serum Atezolizumab Concentration (Cmin)</measure>
    <time_frame>Predose (0 hours) on Day 1 of Cycles 1, 2, 3, 4 and every 8 cycles thereafter; at treatment discontinuation (up to 25 months); at 120 days after last dose of atezolizumab (up to 25 months; each cycle is 21 days)</time_frame>
    <description>Cmin was measured for all participants that received at least one dose of Atezolizumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Objective Response Rate (ORR) as Determined by the Investigator With Use of Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1)</measure>
    <time_frame>Up to approximately 25 months after first participant enrolled</time_frame>
    <description>ORR was defined as the percentage of participants, who had an objective response. Objective response was defined as either a complete response (CR) or partial response (PR) as determined by the investigator with use of Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1). Objective response in this study did not need to be a confirmed response. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. ORR=CR+PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Atezolizumab Concentration (Cmax)</measure>
    <time_frame>30 minutes post dose on Day 1 of Cycles 1</time_frame>
    <description>Cmax was measured for all participants that received at least one dose of Atezolizumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score: Global Health Status Scale</measure>
    <time_frame>Cycle 1 Day 1 (prior to any health care interaction), on Day 1 of each subsequent cycle, and at 30 days after the last treatment dose (Up to approximately 25 months; each cycle is 21 days)</time_frame>
    <description>The EORTC QLQ-C30 includes five functional scales (physical, role, cognitive, emotional, social); a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms). Key scales included physical functioning, and fatigue, and GHS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score: Physical Functioning Scale</measure>
    <time_frame>Cycle 1 Day 1 (prior to any health care interaction), on Day 1 of each subsequent cycle, and at 30 days after the last treatment dose (Up to approximately 25 months; each cycle is 21 days)</time_frame>
    <description>The EORTC QLQ-C30 includes five functional scales (physical, role, cognitive, emotional, social); a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms). Key scales included physical functioning, and fatigue, and GHS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score: Fatigue Symptom Scale</measure>
    <time_frame>Cycle 1 Day 1 (prior to any health care interaction), on Day 1 of each subsequent cycle, and at 30 days after the last treatment dose (Up to approximately 25 months; each cycle is 21 days)</time_frame>
    <description>The EORTC QLQ-C30 includes five functional scales (physical, role, cognitive, emotional, social); a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms). Key scales included physical functioning, and fatigue, and GHS.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">931</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atezolizumab will be administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants will receive atezolizumab as long as they continue to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to the chemotherapy arm will receive vinflunine, paclitaxel, or docetaxel per the investigator's choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody</intervention_name>
    <description>Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Arm A: Atezolizumab</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 175 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinflunine</intervention_name>
    <description>Vinflunine 320 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically documented locally advanced or metastatic UBC
             (including renal pelvis, ureters, urinary bladder, and urethra)

          -  Representative tumor specimens as specified by the protocol

          -  Disease progression during or following treatment with at least one
             platinum-containing regimen for inoperable, locally advanced or metastatic UBC or
             disease recurrence

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Life expectancy greater than or equal to (&gt;/=) 12 weeks

          -  Measurable disease, as defined by RECIST v1.1

          -  Adequate hematologic and end organ function

          -  For women of childbearing potential, agreement to refrain from heterosexual
             intercourse or use contraceptive methods that result in a failure rate of &lt; 1% per
             year during the treatment period and for at least 5 months after the last dose of
             atezolizumab, 3 months after the last dose of vinflunine and 6 months from the last
             dose of paclitaxel or docetaxel.

          -  For men, agreement to refrain from heterosexual intercourse or use contraceptive
             methods that result in a failure rate of &lt; 1% per year during the treatment period and
             for at least 3 months after the last dose of vinflunine and 6 months from the last
             dose of paclitaxel or docetaxel, and agreement to refrain from donating sperm

        Exclusion Criteria:

          -  Any approved anti-cancer therapy within 3 weeks prior to initiation of study treatment

          -  Treatment with any other investigational agent or participation in another clinical
             trial with therapeutic intent within 28 days prior to enrollment

          -  Active or untreated central nervous system (CNS) metastases as determined by computed
             tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and
             prior radiographic assessments

          -  Leptomeningeal disease

          -  Malignancies other than UBC within 5 years prior to Cycle 1, Day 1, with the exception
             of those with a negligible risk of metastasis or death and treated with expected
             curative outcome, or localized prostate cancer treated with curative intent and
             absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer

          -  Pregnant and lactating women

          -  Significant cardiovascular disease

          -  Severe infections within 4 weeks prior to randomization

          -  Major surgical procedure other than for diagnosis within 4 weeks prior to
             randomization

          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric or humanized antibodies or fusion proteins; known hypersensitivity or allergy
             to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the
             atezolizumab formulation

          -  History of autoimmune disease

          -  Prior allogeneic stem cell or solid organ transplant

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest CT scan

          -  Positive test for human immunodeficiency virus (HIV) and/or active hepatitis B or
             hepatitis C or tuberculosis

          -  Administration of a live, attenuated vaccine within 4 weeks prior to randomization

          -  Prior treatment with cluster of differentiation 137 (CD137) agonists or immune
             checkpoint blockade therapies, including anti-cytotoxic T-lymphocyte-associated
             protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1) or anti-programmed
             death-ligand 1 (anti-PD-L1) therapeutic antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University Medical Center Lombardi Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University; Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours - St. Francis Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Ctr</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital; Medical Oncology</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital; Oncology</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre; Oncology</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin and Repatriation Medical Centre; Cancer Services</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser-Franz-Josef-Spital; Zent.Onkologie und Hamatologie</name>
      <address>
        <city>Wien</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre-Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bcca - Cancer Center Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA-Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bcca - Vancouver Island Cancer Centre; Oncology</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Oshawa; Oncology</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre; Oncology</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sault Area Hospitals</name>
      <address>
        <city>Sault Ste Marie</city>
        <state>Ontario</state>
        <zip>P6A 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masarykuv onkologicky ustav</name>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MULTISCAN, s.r.o., Radiologicke centrum Pardubice</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Kralovske Vinohrady</name>
      <address>
        <city>Praha</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital; Onkologisk afdeling</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Onkologisk Klinik</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Docrates Cance Center</name>
      <address>
        <city>Helsinki</city>
        <zip>00180</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Central Hospital; Urology clinic</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ico - Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine;Recherche Clinique</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chr De Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie; Oncologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse; Recherche Clinique</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor; Service d'Oncologie Medicale</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Chenieux; Oncology</name>
      <address>
        <city>Limoges</city>
        <zip>87039</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard; Departement Oncologie Medicale</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut J Paolii Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut régional du Cancer Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre D'Oncologie de Gentilly; Oncology</name>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU De Nimes, Hopital Caremeau; Service De Neurologie Du Prof. Pierre Labauge</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin; Unite Fonctionnelle D Oncologie</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie; Recherche Clinique</name>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis; Oncologie Medicale</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen - Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO - Site René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Hautepierre; Hematologie Oncologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Foch; Oncologie</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud; Departement Oncologie Medicale</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy; Departement Oncologie Medicale</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen; Klinik für Urologie</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin; CC 8: Chirurgische Medizin; Klinik für Urologie</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum &quot;Carl Gustav Carus&quot;; Klinik und Poliklinik für Urologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf; Urologische Klinik</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friedrich-Alexander-Universität Erlangen-Nürnberg; Medizinische Klinik V</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg; Chirurgische Klinik; Abteilung Urologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen Georg-August-Universität; Klinik für Urologie</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationales Centrum für Tumorerkrankungen Heidelberg (NCT); Thoraxklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes; Klinik für Urologie und Kinderurologie</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg A.ö.R., Klinik f. Urologie u. Kinderurologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultät Mannheim, Universitätsklinikum Mannheim, Klinik für Urologie</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen; Klinik für Urologie</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm; Klinik für Urologie</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandras General Hospital of Athens; Oncology Department</name>
      <address>
        <city>Athens</city>
        <zip>115 28</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ General Hosp Heraklion; Medical Oncology</name>
      <address>
        <city>Heraklion</city>
        <zip>711 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras Medical Oncology</name>
      <address>
        <city>Patras</city>
        <zip>265 04</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Euromedical General Clinic of Thessaloniki; Oncology Department</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 45</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelwies University of Medicine; Urology Dept.</name>
      <address>
        <city>Budapest</city>
        <zip>1082</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologiai Intezet; &quot;C&quot; Belgyógyászati-Onkológiai és Klinikai Farmakológiai Osztály</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzsoki Utcai Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kecskemeti Onkoradilogai Centrum</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hetenyi Geza County Hospital; Onkologiai Kozpont</name>
      <address>
        <city>Szolnok</city>
        <zip>5004</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera A. Cardarelli; Dip. Oncopneumoematologico</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica</name>
      <address>
        <city>Meldola</city>
        <state>Emilia-Romagna</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico Di Modena; Oncologia</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia</name>
      <address>
        <city>Udine</city>
        <state>Friuli-Venezia Giulia</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo Forlanini; Oncologia Medica</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asst Papa Giovanni XXIII; Oncologia Medica</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST DI CREMONA; Dip. Medicina - S.C. Oncologia</name>
      <address>
        <city>Cremona</city>
        <state>Lombardia</state>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico</name>
      <address>
        <city>Candiolo</city>
        <state>Piemonte</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Puglia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa Di Cura Di Alta Specialita La Maddalena; Dept. Oncologico Di Iii Livello</name>
      <address>
        <city>Palermo</city>
        <state>Sicilia</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia</name>
      <address>
        <city>Arezzo</city>
        <state>Toscana</state>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital; Urology</name>
      <address>
        <city>Aichi</city>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirosaki University School of Medicine &amp; Hospital; Urology</name>
      <address>
        <city>Aomori</city>
        <zip>036-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba Cancer Center; Urology</name>
      <address>
        <city>Chiba</city>
        <zip>260-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East; Breast and Medical Oncology</name>
      <address>
        <city>Chiba</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center; Urology</name>
      <address>
        <city>Ehime</city>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harasanshin Hospital; Urology</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital; Urology</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma University Hospital; Urology</name>
      <address>
        <city>Gunma</city>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Hiroshima Citizens Hospital; Urology</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Medical University Hospital; Urology</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital; Urology</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital; Urology</name>
      <address>
        <city>Ibaraki</city>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Hospital; Urology</name>
      <address>
        <city>Iwate</city>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Hospital; Urology</name>
      <address>
        <city>Kanagawa</city>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital; Urology</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital;Urology</name>
      <address>
        <city>Niigata</city>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute; Urology</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital; Urology</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital; Urology</name>
      <address>
        <city>Osaka</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center; Urology</name>
      <address>
        <city>Shizuoka</city>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokushima University Hospital; Urology</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital; Urology</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital; Medical Oncology</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Hospital; Urology</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital, JFCR; Urology</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute - Antoni Van Leeuwenhoekziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis; Inwendige Geneeskunde</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Centre; Medical Oncology</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis Nieuwegein</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>8011 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sørlandet Sykehus Kristiansand</name>
      <address>
        <city>Kristiansand</city>
        <zip>4604</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni Hospital of Tromso; Dept. of Oncology</name>
      <address>
        <city>Tromsø</city>
        <zip>9019</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital; Kreftavdelingen</name>
      <address>
        <city>Trondheim</city>
        <zip>7000</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Bialystok; Oncology clinic</name>
      <address>
        <city>Bialystok</city>
        <zip>15-027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Chemioterapii Szpitala Klinicznego Nr 1 w Poznaniu</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum onkologii Instytutu im. Marii Sklodowskiej-Curie; Klinika Nowotworow Ukladu Moczowego</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny im. Jana Miklulicza-Radeckiego we Wrocławiu; Departament Of Urology</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria; Servico de Oncologia Medica</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Beatriz Angelo; Departamento de Oncologia</name>
      <address>
        <city>Loures</city>
        <zip>2674-514</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPO do Porto; Servico de Oncologia Medica</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean de Urgenta Dr Constantin Opris</name>
      <address>
        <city>Baia Mare</city>
        <zip>430031</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Of Oncology Bucharest; Medical Oncology</name>
      <address>
        <city>Bucharest</city>
        <zip>022338</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Oncologic Ion Chiricuta; Departament Radioterapie</name>
      <address>
        <city>Cluj-napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Center Sf. Nectarie</name>
      <address>
        <city>Craiova</city>
        <zip>200347</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Euroclinic Center of Oncology SRL</name>
      <address>
        <city>Iasi</city>
        <zip>700106</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spital Clinic Judetean Mures; Oncologie</name>
      <address>
        <city>Targu Mures</city>
        <zip>540142</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ONCOMED - Medical Centre</name>
      <address>
        <city>Timisoara</city>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ Nizhegorodskay Region: Clinical Diagnostic Center</name>
      <address>
        <city>Nizhni Novgorod</city>
        <state>Niznij Novgorod</state>
        <zip>603001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altai Regional Oncological Center</name>
      <address>
        <city>Barnaul</city>
        <zip>656049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution, Moscow Research Oncology Institute n.a. P.A. Hertzen; Oncourology</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg Oncology Hospital</name>
      <address>
        <city>St Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Stavropol</city>
        <zip>355045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia; Clinic of Urology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Oncology and Radiology of Serbia; Medical Oncology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Vojvodina</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli; Servicio de Oncologia</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia; Servicio de Oncologia</name>
      <address>
        <city>Córdoba</city>
        <state>Cordoba</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases; Servicio de Oncologia</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>LA Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra; Servicio de Oncologia</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial; Servicio de Farmacia</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala d Oncologia Hospital Duran i Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro De Alcantara; Servicio de Oncologia</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra; Servicio de Oncologia</name>
      <address>
        <city>Navarra</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio; Servicio de Oncologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia; Servicio de oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia; Servicio de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset; Jubileumskliniken</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Hospital; Oncology - Radiumhemmet</name>
      <address>
        <city>Solna</city>
        <zip>171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrlands Uni Hospital; Onkologi Avd.</name>
      <address>
        <city>Umea</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern; Medizinische Onkologie</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden;Onkologie und Hämatologie</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUG; Oncologie</name>
      <address>
        <city>Geneve</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen; Onkologie/Hämatologie</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital; Urology</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital; Division of Urology</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan Uni Hospital; Dept of Oncology</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TAIPEI VETERANS GENERAL HOSPITAL, Urology</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uludag Uni Hospital; Oncology</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department</name>
      <address>
        <city>Edirne</city>
        <zip>22770</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bezmialem Vakif Univ Medical</name>
      <address>
        <city>Istanbul</city>
        <zip>34286</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology</name>
      <address>
        <city>Istanbul</city>
        <zip>34300</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul VKV American Hospital; Medical Oncology</name>
      <address>
        <city>Istanbul</city>
        <zip>34365</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege Uni Medical Faculty Hospital; Oncology Dept</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department</name>
      <address>
        <city>Malatya</city>
        <zip>44280</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe Uni Medical Faculty Hospital; Oncology Dept</name>
      <address>
        <city>Sıhhiye, Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham The Cancer Centre, Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <zip>GL53 7AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital coventry; Oncology Department</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter Hospital; Oncology Centre</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Lancaster Infirmary, Morecambe Bay Hospitals Nhs Trust</name>
      <address>
        <city>Lancaster</city>
        <zip>LA1 4RP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James Institute of Oncology</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary; Dept. of Medical Oncology</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts and The London</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital; Dept of Oncology</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Care; Northern Centre for Cancer Care</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scunthorpe General Hospital; Dept of Oncology</name>
      <address>
        <city>Scunthorpe</city>
        <zip>DN16 7BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital; Medical Oncology</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital; Dept of Medical Oncology</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre NHS Foundation Trust</name>
      <address>
        <city>Wirral</city>
        <zip>L63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2014</study_first_submitted>
  <study_first_submitted_qc>November 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <results_first_submitted>March 13, 2018</results_first_submitted>
  <results_first_submitted_qc>March 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 11, 2018</results_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)</title>
          <description>Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Atezolizumab</title>
          <description>Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="464"/>
                <participants group_id="P2" count="467"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="443"/>
                <participants group_id="P2" count="459"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="375"/>
                <participants group_id="P2" count="334"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="345"/>
                <participants group_id="P2" count="322"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)</title>
          <description>Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Atezolizumab</title>
          <description>Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="464"/>
            <count group_id="B2" value="467"/>
            <count group_id="B3" value="931"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.1" spread="9.3"/>
                    <measurement group_id="B2" value="65.9" spread="9.6"/>
                    <measurement group_id="B3" value="66.0" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="213"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="361"/>
                    <measurement group_id="B2" value="357"/>
                    <measurement group_id="B3" value="718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="368"/>
                    <measurement group_id="B2" value="363"/>
                    <measurement group_id="B3" value="731"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="336"/>
                    <measurement group_id="B2" value="335"/>
                    <measurement group_id="B3" value="671"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as time from randomization to death from any cause.</description>
        <time_frame>Between randomization and death due to any cause, up to approximately 25 months after first participant enrolled</time_frame>
        <population>Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>IC2/3 Chemotherapy</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC2/3</description>
          </group>
          <group group_id="O2">
            <title>IC2/3 Atezolizumab</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC2/3</description>
          </group>
          <group group_id="O3">
            <title>IC1/2/3 Chemotherapy</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC1/2/3</description>
          </group>
          <group group_id="O4">
            <title>IC1/2/3 Atezolizumab</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC1/2/3</description>
          </group>
          <group group_id="O5">
            <title>Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)</title>
            <description>Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Atezolizumab</title>
            <description>Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as time from randomization to death from any cause.</description>
          <population>Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="309"/>
                <count group_id="O4" value="316"/>
                <count group_id="O5" value="464"/>
                <count group_id="O6" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="8.4" upper_limit="12.2"/>
                    <measurement group_id="O2" value="11.1" lower_limit="8.6" upper_limit="15.5"/>
                    <measurement group_id="O3" value="8.2" lower_limit="7.4" upper_limit="9.5"/>
                    <measurement group_id="O4" value="8.9" lower_limit="8.2" upper_limit="10.9"/>
                    <measurement group_id="O5" value="8.0" lower_limit="7.2" upper_limit="8.6"/>
                    <measurement group_id="O6" value="8.6" lower_limit="7.8" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4134</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1392</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0378</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) as Determined by the Investigator With Use of RECIST v1.1</title>
        <description>PFS was defined as the time between the date of randomization and the date of first documented progression of disease (PD) or death, whichever occurred first. PD was determined on the basis of investigator assessment with use of RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters had to demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
        <time_frame>Up to approximately 25 months after first participant enrolled</time_frame>
        <population>Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)</title>
            <description>Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab</title>
            <description>Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.</description>
          </group>
          <group group_id="O3">
            <title>IC2/3 Chemotherapy</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC2/3</description>
          </group>
          <group group_id="O4">
            <title>IC2/3 Atezolizumab</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC2/3</description>
          </group>
          <group group_id="O5">
            <title>IC1/2/3 Chemotherapy</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC1/2/3</description>
          </group>
          <group group_id="O6">
            <title>IC1/2/3 Atezolizumab</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC1/2/3</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) as Determined by the Investigator With Use of RECIST v1.1</title>
          <description>PFS was defined as the time between the date of randomization and the date of first documented progression of disease (PD) or death, whichever occurred first. PD was determined on the basis of investigator assessment with use of RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters had to demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
          <population>Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="467"/>
                <count group_id="O3" value="118"/>
                <count group_id="O4" value="116"/>
                <count group_id="O5" value="309"/>
                <count group_id="O6" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="3.4" upper_limit="4.2"/>
                    <measurement group_id="O2" value="2.1" lower_limit="2.1" upper_limit="2.2"/>
                    <measurement group_id="O3" value="4.1" lower_limit="3.6" upper_limit="4.2"/>
                    <measurement group_id="O4" value="2.4" lower_limit="2.1" upper_limit="4.2"/>
                    <measurement group_id="O5" value="4.1" lower_limit="3.6" upper_limit="4.2"/>
                    <measurement group_id="O6" value="2.1" lower_limit="2.1" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR) as Determined by the Investigator With Use of RECIST v1.1</title>
        <description>DOR was defined as the time from first occurrence of a CR or PR, whichever came first, to first documented PD or death, whichever occurred first. Disease progression was determined on the basis of investigator assessment with use of RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
        <time_frame>Up to approximately 25 months after first participant enrolled</time_frame>
        <population>DOR analyses was performed on the subset of patients who achieved an objective response.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)</title>
            <description>Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab</title>
            <description>Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.</description>
          </group>
          <group group_id="O3">
            <title>IC2/3 Chemotherapy</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC2/3</description>
          </group>
          <group group_id="O4">
            <title>IC2/3 Atezolizumab</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC2/3</description>
          </group>
          <group group_id="O5">
            <title>IC1/2/3 Chemotherapy</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC1/2/3</description>
          </group>
          <group group_id="O6">
            <title>IC1/2/3 Atezolizumab</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC1/2/3</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR) as Determined by the Investigator With Use of RECIST v1.1</title>
          <description>DOR was defined as the time from first occurrence of a CR or PR, whichever came first, to first documented PD or death, whichever occurred first. Disease progression was determined on the basis of investigator assessment with use of RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
          <population>DOR analyses was performed on the subset of patients who achieved an objective response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="4.2" upper_limit="6.3"/>
                    <measurement group_id="O2" value="21.7" lower_limit="9.9" upper_limit="21.7"/>
                    <measurement group_id="O3" value="6.4" lower_limit="4.2" upper_limit="8.3"/>
                    <measurement group_id="O4" value="13.0" lower_limit="6.6">Explanation needed from study team.</measurement>
                    <measurement group_id="O5" value="5.5" lower_limit="4.2" upper_limit="7.4"/>
                    <measurement group_id="O6" value="13" lower_limit="6.9">Explanation needed from study team.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs)</title>
        <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
        <time_frame>Up to approximately 25 months after first participant enrolled</time_frame>
        <population>Safety analyses was performed on all randomized patients who received any amount of study treatment, with patients grouped according to whether any amount of atezolizumab was received including the case when atezolizumab was received in error.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)</title>
            <description>Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab</title>
            <description>Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.</description>
          </group>
          <group group_id="O3">
            <title>IC2/3 Chemotherapy</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC2/3</description>
          </group>
          <group group_id="O4">
            <title>IC2/3 Atezolizumab</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC2/3</description>
          </group>
          <group group_id="O5">
            <title>IC1/2/3 Chemotherapy</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC1/2/3</description>
          </group>
          <group group_id="O6">
            <title>IC1/2/3 Atezolizumab</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC1/2/3</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs)</title>
          <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
          <population>Safety analyses was performed on all randomized patients who received any amount of study treatment, with patients grouped according to whether any amount of atezolizumab was received including the case when atezolizumab was received in error.</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="459"/>
                <count group_id="O3" value="112"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="297"/>
                <count group_id="O6" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2"/>
                    <measurement group_id="O2" value="95.4"/>
                    <measurement group_id="O3" value="98.2"/>
                    <measurement group_id="O4" value="97.4"/>
                    <measurement group_id="O5" value="98.7"/>
                    <measurement group_id="O6" value="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-therapeutic Antibodies (ATA) to Atezolizumab</title>
        <description>Participants were considered post-baseline ATA positive if they had post-baseline ATAs to Atezolizumab that were treatment-induced or treatment-enhanced. Participants had treatment-induced ATAs if they had a baseline-negative ATA result and developed ATAs at any time after initial drug administration. Participants had treatment-enhanced ATAs if they had a baseline-positive ATA result that showed an enhanced signal that was &gt;/= 0.60 titer units at any time after initial drug initiation.</description>
        <time_frame>Predose (0 hours) on Day 1 of Cycles 1, 2, 3, 4 and every 8 cycles thereafter; at treatment discontinuation (up to 25 months); at 120 days after last dose of atezolizumab (up to 25 months; each cycle is 21 days)</time_frame>
        <population>ATA evaluable population is defined as patients who received atezolizumab treatment and had at least one post-treatment ATA result.</population>
        <group_list>
          <group group_id="O1">
            <title>Atezolizumab</title>
            <description>Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>IC1/2/3 Atezolizumab</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC2/3</description>
          </group>
          <group group_id="O3">
            <title>IC2/3 Atezolizumab</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC2/3</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-therapeutic Antibodies (ATA) to Atezolizumab</title>
          <description>Participants were considered post-baseline ATA positive if they had post-baseline ATAs to Atezolizumab that were treatment-induced or treatment-enhanced. Participants had treatment-induced ATAs if they had a baseline-negative ATA result and developed ATAs at any time after initial drug administration. Participants had treatment-enhanced ATAs if they had a baseline-positive ATA result that showed an enhanced signal that was &gt;/= 0.60 titer units at any time after initial drug initiation.</description>
          <population>ATA evaluable population is defined as patients who received atezolizumab treatment and had at least one post-treatment ATA result.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="289"/>
                <count group_id="O3" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="33.0"/>
                    <measurement group_id="O3" value="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Observed Serum Atezolizumab Concentration (Cmin)</title>
        <description>Cmin was measured for all participants that received at least one dose of Atezolizumab.</description>
        <time_frame>Predose (0 hours) on Day 1 of Cycles 1, 2, 3, 4 and every 8 cycles thereafter; at treatment discontinuation (up to 25 months); at 120 days after last dose of atezolizumab (up to 25 months; each cycle is 21 days)</time_frame>
        <population>The PK-evaluable population is defined as patients who received atezolizumab treatment and had at least one measureable PK concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Atezolizumab</title>
            <description>Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Observed Serum Atezolizumab Concentration (Cmin)</title>
          <description>Cmin was measured for all participants that received at least one dose of Atezolizumab.</description>
          <population>The PK-evaluable population is defined as patients who received atezolizumab treatment and had at least one measureable PK concentration.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 2, day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3, day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1" spread="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4, day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122" spread="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8, day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159" spread="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16, day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" spread="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 24, day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" spread="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 32, day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223" spread="87.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Objective Response Rate (ORR) as Determined by the Investigator With Use of Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1)</title>
        <description>ORR was defined as the percentage of participants, who had an objective response. Objective response was defined as either a complete response (CR) or partial response (PR) as determined by the investigator with use of Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1). Objective response in this study did not need to be a confirmed response. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. ORR=CR+PR</description>
        <time_frame>Up to approximately 25 months after first participant enrolled</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)</title>
            <description>Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab</title>
            <description>Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.</description>
          </group>
          <group group_id="O3">
            <title>IC2/3 Chemotherapy</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC2/3</description>
          </group>
          <group group_id="O4">
            <title>IC2/3 Atezolizumab</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC2/3</description>
          </group>
          <group group_id="O5">
            <title>IC1/2/3 Chemotherapy</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC1/2/3</description>
          </group>
          <group group_id="O6">
            <title>IC1/2/3 Atezolizumab</title>
            <description>PD-L1 immunohistochemistry (IHC) score of IC1/2/3</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Objective Response Rate (ORR) as Determined by the Investigator With Use of Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1)</title>
          <description>ORR was defined as the percentage of participants, who had an objective response. Objective response was defined as either a complete response (CR) or partial response (PR) as determined by the investigator with use of Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1). Objective response in this study did not need to be a confirmed response. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. ORR=CR+PR</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="461"/>
                <count group_id="O2" value="462"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="113"/>
                <count group_id="O5" value="306"/>
                <count group_id="O6" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" lower_limit="17.21" upper_limit="24.82"/>
                    <measurement group_id="O2" value="15.4" lower_limit="12.20" upper_limit="18.99"/>
                    <measurement group_id="O3" value="29.3" lower_limit="21.23" upper_limit="38.48"/>
                    <measurement group_id="O4" value="26.5" lower_limit="18.68" upper_limit="35.68"/>
                    <measurement group_id="O5" value="22.2" lower_limit="17.69" upper_limit="27.30"/>
                    <measurement group_id="O6" value="16.3" lower_limit="12.42" upper_limit="20.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Atezolizumab Concentration (Cmax)</title>
        <description>Cmax was measured for all participants that received at least one dose of Atezolizumab.</description>
        <time_frame>30 minutes post dose on Day 1 of Cycles 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atezolizumab</title>
            <description>Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Atezolizumab Concentration (Cmax)</title>
          <description>Cmax was measured for all participants that received at least one dose of Atezolizumab.</description>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334" spread="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score: Global Health Status Scale</title>
        <description>The EORTC QLQ-C30 includes five functional scales (physical, role, cognitive, emotional, social); a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms). Key scales included physical functioning, and fatigue, and GHS.</description>
        <time_frame>Cycle 1 Day 1 (prior to any health care interaction), on Day 1 of each subsequent cycle, and at 30 days after the last treatment dose (Up to approximately 25 months; each cycle is 21 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)</title>
            <description>Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab</title>
            <description>Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score: Global Health Status Scale</title>
          <description>The EORTC QLQ-C30 includes five functional scales (physical, role, cognitive, emotional, social); a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms). Key scales included physical functioning, and fatigue, and GHS.</description>
          <units>Participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="408"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Cycle 1, Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.49" spread="22.30"/>
                    <measurement group_id="O2" value="64.19" spread="21.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 2, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.47" spread="20.02"/>
                    <measurement group_id="O2" value="-6.18" spread="20.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 3, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.76" spread="22.34"/>
                    <measurement group_id="O2" value="-4.67" spread="20.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 4, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="19.71"/>
                    <measurement group_id="O2" value="-0.53" spread="20.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 12, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.95" spread="24.33"/>
                    <measurement group_id="O2" value="-0.56" spread="22.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 20, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.27" spread="16.28"/>
                    <measurement group_id="O2" value="1.10" spread="21.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 28, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.67" spread="7.45"/>
                    <measurement group_id="O2" value="-5.26" spread="33.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline:Treatment Discont. Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.77" spread="24.15"/>
                    <measurement group_id="O2" value="-16.71" spread="24.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score: Physical Functioning Scale</title>
        <description>The EORTC QLQ-C30 includes five functional scales (physical, role, cognitive, emotional, social); a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms). Key scales included physical functioning, and fatigue, and GHS.</description>
        <time_frame>Cycle 1 Day 1 (prior to any health care interaction), on Day 1 of each subsequent cycle, and at 30 days after the last treatment dose (Up to approximately 25 months; each cycle is 21 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)</title>
            <description>Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab</title>
            <description>Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score: Physical Functioning Scale</title>
          <description>The EORTC QLQ-C30 includes five functional scales (physical, role, cognitive, emotional, social); a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms). Key scales included physical functioning, and fatigue, and GHS.</description>
          <units>Participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="408"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Cycle 1, Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.23" spread="22.55"/>
                    <measurement group_id="O2" value="76.37" spread="19.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 2, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.80" spread="15.70"/>
                    <measurement group_id="O2" value="-7.56" spread="18.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 3, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.64" spread="17.37"/>
                    <measurement group_id="O2" value="-7.06" spread="19.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 4, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.41" spread="16.25"/>
                    <measurement group_id="O2" value="-3.81" spread="17.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 12, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.97" spread="20.20"/>
                    <measurement group_id="O2" value="0.89" spread="16.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 20, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.03" spread="11.30"/>
                    <measurement group_id="O2" value="3.48" spread="13.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 28, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.67" spread="24.68"/>
                    <measurement group_id="O2" value="3.51" spread="20.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Treatment Discont. Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.58" spread="25.67"/>
                    <measurement group_id="O2" value="-20.19" spread="25.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score: Fatigue Symptom Scale</title>
        <description>The EORTC QLQ-C30 includes five functional scales (physical, role, cognitive, emotional, social); a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms). Key scales included physical functioning, and fatigue, and GHS.</description>
        <time_frame>Cycle 1 Day 1 (prior to any health care interaction), on Day 1 of each subsequent cycle, and at 30 days after the last treatment dose (Up to approximately 25 months; each cycle is 21 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)</title>
            <description>Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab</title>
            <description>Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score: Fatigue Symptom Scale</title>
          <description>The EORTC QLQ-C30 includes five functional scales (physical, role, cognitive, emotional, social); a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms). Key scales included physical functioning, and fatigue, and GHS.</description>
          <units>Participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="408"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue Symptom: Baseline (Cycle 1, Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.67" spread="26.66"/>
                    <measurement group_id="O2" value="32.87" spread="23.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Symptom: Cycle 2, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.71" spread="23.13"/>
                    <measurement group_id="O2" value="10.56" spread="21.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 3, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.04" spread="25.48"/>
                    <measurement group_id="O2" value="9.41" spread="24.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 4, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.48" spread="22.63"/>
                    <measurement group_id="O2" value="3.67" spread="23.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 12, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.70" spread="27.44"/>
                    <measurement group_id="O2" value="-0.95" spread="23.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 20, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.11" spread="28.97"/>
                    <measurement group_id="O2" value="-8.05" spread="21.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Cycle 28, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.56" spread="16.85"/>
                    <measurement group_id="O2" value="-12.28" spread="28.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline: Treatment Discont. Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.27" spread="28.15"/>
                    <measurement group_id="O2" value="19.60" spread="25.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first study drug to the data cutoff date: 13 March 2017 (up to 25 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)</title>
          <description>Participants randomized to the chemotherapy arm will receive vinflunine, paclitaxel, or docetaxel per the investigator's choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Atezolizumab</title>
          <description>Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="343" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="318" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="191" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="188" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="443"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Bone Marrow Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Macular Fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Visual Impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="443"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Anal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Autoimmune Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Colitis Ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Duodenal Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Eterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Eterovesical Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Functional Gastrointestinal Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Gastric Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Ileal Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Jejunal Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Large Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="443"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="443"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Multiple Organ Dysfunction Syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="443"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Peripheral Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="443"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Strangulated Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Bile Duct Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Biliary Dilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hepatocellular Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Portal Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis Infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Enterococcal Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Enterococcal Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Escherichia Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Escherichia Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Escherichia Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Kidney Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Klebsiella Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis Viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Neutropenic Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Neutropenic Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Ophthalmic Herpes Zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="443"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="443"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Spinal Cord Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Toxic Shock Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="443"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infusion Related Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Lumbar Vertebral Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Stoma Site Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Toxicity to Various Agents</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Urostomy Complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Blood Calcium Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Liver Function Test Abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Failure to Thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="443"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Groin Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pathological Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Peripheral Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Mantle Cell Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Neoplasm Malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Tumor Associated Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Spinal Cord Compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Device Occlusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="443"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Bladder Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Bladder Tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="443"/>
                <counts group_id="E2" events="18" subjects_affected="9" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Postrenal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="443"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Renal Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Urethral Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Urinary Bladder Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Urinary Tract Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Urinary Tract Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Urinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Toxic Epidermal Necrolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominal Cavity Drainage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Vertebroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="416" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="408" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="141" subjects_affected="123" subjects_at_risk="443"/>
                <counts group_id="E2" events="92" subjects_affected="88" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="72" subjects_affected="55" subjects_at_risk="443"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="63" subjects_affected="58" subjects_at_risk="443"/>
                <counts group_id="E2" events="56" subjects_affected="49" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="32" subjects_affected="27" subjects_at_risk="443"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="219" subjects_affected="162" subjects_at_risk="443"/>
                <counts group_id="E2" events="135" subjects_affected="121" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="115" subjects_affected="94" subjects_at_risk="443"/>
                <counts group_id="E2" events="122" subjects_affected="90" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="443"/>
                <counts group_id="E2" events="33" subjects_affected="28" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="170" subjects_affected="136" subjects_at_risk="443"/>
                <counts group_id="E2" events="115" subjects_affected="99" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="41" subjects_affected="35" subjects_at_risk="443"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="106" subjects_affected="79" subjects_at_risk="443"/>
                <counts group_id="E2" events="63" subjects_affected="52" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="140" subjects_affected="105" subjects_at_risk="443"/>
                <counts group_id="E2" events="100" subjects_affected="88" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="163" subjects_affected="137" subjects_at_risk="443"/>
                <counts group_id="E2" events="144" subjects_affected="124" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" events="64" subjects_affected="47" subjects_at_risk="443"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="41" subjects_affected="36" subjects_at_risk="443"/>
                <counts group_id="E2" events="54" subjects_affected="48" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="36" subjects_affected="33" subjects_at_risk="443"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="76" subjects_affected="63" subjects_at_risk="443"/>
                <counts group_id="E2" events="117" subjects_affected="86" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="443"/>
                <counts group_id="E2" events="36" subjects_affected="26" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="73" subjects_affected="56" subjects_at_risk="443"/>
                <counts group_id="E2" events="118" subjects_affected="79" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="443"/>
                <counts group_id="E2" events="37" subjects_affected="35" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="48" subjects_affected="25" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" events="46" subjects_affected="45" subjects_at_risk="443"/>
                <counts group_id="E2" events="44" subjects_affected="44" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="133" subjects_affected="110" subjects_at_risk="443"/>
                <counts group_id="E2" events="141" subjects_affected="131" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="443"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="80" subjects_affected="60" subjects_at_risk="443"/>
                <counts group_id="E2" events="62" subjects_affected="48" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="53" subjects_affected="51" subjects_at_risk="443"/>
                <counts group_id="E2" events="90" subjects_affected="80" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="443"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="68" subjects_affected="55" subjects_at_risk="443"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="54" subjects_affected="47" subjects_at_risk="443"/>
                <counts group_id="E2" events="46" subjects_affected="37" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="32" subjects_affected="30" subjects_at_risk="443"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="443"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="35" subjects_affected="26" subjects_at_risk="443"/>
                <counts group_id="E2" events="39" subjects_affected="34" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" events="63" subjects_affected="53" subjects_at_risk="443"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="443"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" events="43" subjects_affected="41" subjects_at_risk="443"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="443"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="443"/>
                <counts group_id="E2" events="44" subjects_affected="42" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="443"/>
                <counts group_id="E2" events="56" subjects_affected="44" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="443"/>
                <counts group_id="E2" events="58" subjects_affected="55" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="47" subjects_affected="43" subjects_at_risk="443"/>
                <counts group_id="E2" events="64" subjects_affected="59" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="126" subjects_affected="124" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="26" subjects_affected="19" subjects_at_risk="443"/>
                <counts group_id="E2" events="78" subjects_affected="63" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="37" subjects_affected="28" subjects_at_risk="443"/>
                <counts group_id="E2" events="60" subjects_affected="52" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

